Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of small-cap biotech Delcath Systems
So what: The unconfirmed rumor has drug giant Bristol-Myers Squibb
Now what: Fools know never to jump into a stock on takeover speculation alone. But with Delcath recently validating positive trial results for its drug delivery system, as well as raising about $35 million in a secondary offering, the stock does sport some serious hidden potential. If Delcath gets its PHP system approved by mid-2011, like its CFO expects, today's speculation-fueled surge will likely be a drop in the bucket.
Update: On Friday, Oct. 8, Delcath shares moved an additional 14% in intraday trading on no new news.
True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool has a disclosure policy.